Does this mean it's time to dump your Moderna shares? First, it's important to note that Moderna's difficult times may not be over.

Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as it works to develop its product portfolio while cutting costs.

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option.

The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above.

The Department of Health and Human Services (HHS) is canceling hundreds of millions of dollars in funding pledged to Moderna to help the company develop, test and license mRNA-based vaccines to com… ...

The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu.

Moderna's (MRNA) stock rose more than 3% in trading on Thursday despite an announcement that the National Institutes of Health (NIH), led by Robert F. Kennedy Jr., is ending a $750 million-plus ...

HHS has notified Moderna that it is canceling a nearly $600 million contract for vaccines for flu strains that could trigger future pandemics.

Shares of Moderna surged to lead S&P 500 gainers Tuesday after the Food and Drug Administration issued new guidance for COVID-19 vaccine boosters.

Why Vaccine-Maker Moderna Is Injecting AI Across the Company More than 3,000 GPTs are reportedly in use at Moderna, which has partnered with OpenAI.